Excellent2 Sep 2020 08:48
Stella half yearly results to 30th June. Revenue effectively maintained at 2019 levels notwithstanding pandemic and let's not forget cyber issue.
Cash going forward of $13.8m, new contract with top 10 global pharma, capacity increase Stateside well under way and rejig in Leeds. Costs pruning underway.
Only bug bear for me is now historical: fundraise on back of unnecessary huge dilution (in my view).
Onwards!